Polaris Group, a biopharmaceutical company, has acquired Genovior Biotech, a contract development and manufacturing organization (CDMO). Also, Steve Hsu, chairman of Genovior, has been appointed CEO of Polaris.

The acquisition expands Polaris Group’s product pipeline beyond its novel cancer metabolism therapy into the realm of peptide drugs, such as the widely recognized Semaglutide-related products. These two highly prospective product lines will support Polaris Group’s future growth efforts.

Hsu has over 30 years of professional experience in the pharmaceutical industry. His expertise extends to peptide drugs with over thirty amino acids, achieving exceptionally high yields through synthesis or semi-synthesis approach. Under his leadership, Genovior Biotech has successfully developed the drug Semaglutide for diabetes and weight management. Polaris intends to commence large-scale production based on this achievement, with anticipated mass product shipments starting 2H24.